Şunu aradınız:: farmakodinamičnimi (Slovence - İngilizce)

razmerje med farmakokinetičnimi in farmakodinamičnimi lastnostmi zdravila
pharmacokinetic/pharmacodynamic relationship

zvišanje belih krvnih celic je v skladu s farmakodinamičnimi učinki lipegfilgrastima.
elevation in white blood cells (wbc) is consistent with the pharmacodynamic effects of lipegfilgrastim.

s farmakodinamičnimi študijami so dokazali, da je stopnja baktericidnosti moksifloksacina odvisna od njegove koncentracije.
pharmacodynamic investigations have demonstrated that moxifloxacin exhibits a concentration dependent killing rate.

zaradi nastajanja nevtralizirajočih protiteles so se farmakodinamičnimi učinki romiplostima pri podganah med dolgotrajno uporabo pogosto zmanjševali.
due to the formation of neutralising antibodies pharmacodynamic effects of romiplostim in rats were often decreasing at prolonged duration of administration.

v skladu s farmakodinamičnimi raziskavami izkazuje ciprofloksacin, podobno kot drugi fluorokinoloni, delovanje, ki je odvisno od koncentracije.
according to pharmacodynamic studies, ciprofloxacin, like other fluoroquinolones, exhibits concentration dependent killing.

opazovanja lahko trajajo dlje kot pri običajnih študijah o toksičnosti, pri čemer se upošteva pričakovana življenjska doba zdravila skupaj s farmakodinamičnimi in farmakokinetičnimi lastnostmi.
the duration of observations may be longer than in standard toxicity studies and the anticipated lifespan of the medicinal product, together with its pharmacodynamic and pharmacokinetic profile, shall be taken into consideration.

to je skladno tudi z znanimi farmakodinamičnimi učinki dodajanja progestogenov endometriju, npr. regulacijsko zmanjšanje ravni receptorjev za estrogen (er) in atrofijo endometrija.
this observation is also consistent with the known pharmacodynamic effects of added progestogens on the endometrium, e. g. down regulation of oestrogen receptor (er) levels and endometrial atrophy.

pričakovani neželeni učinki, vključno s slabostjo, bruhanjem, hiperkinezijo, halucinacijami, agitacijo in hipotenzijo, bi morali biti povezani s farmakodinamičnimi lastnostmi dopaminskih agonistov.
the expected adverse events would be those related to the pharmacodynamic profile of a dopamine agonist, including nausea, vomiting, hyperkinesia, hallucinations, agitation and hypotension.

raziskovalec se mora seznaniti z zaključki farmakoloških in toksikoloških raziskav in vlagatelj mu mora predložiti vsaj brošuro za raziskovalca, ki sestoji iz vseh pomembnih informacij, ki so bile poznane pred začetkom kliničnega preskušanja, vključno s kemijskimi, farmacevtskimi in biološkimi podatki, toksikološkimi, farmakokinetičnimi in farmakodinamičnimi podatki pri živalih ter rezultati prejšnjih kliničnih preskušanj, z ustreznimi podatki, ki utemeljujejo vrsto, obseg in trajanje predlaganega preskušanja;
the investigator must acquaint himself with the conclusions drawn from the pharmacological and toxicological studies and hence the applicant must provide him at least with the investigator's brochure, consisting of all the relevant information known prior to the onset of a clinical trial including chemical, pharmaceutical and biological data, toxicological, pharmacokinetic and pharmacodynamic data in animals and the results of earlier clinical trials, with adequate data to justify the nature, scale and duration of the proposed trial;